PUBLISHER: Allied Market Research | PRODUCT CODE: 1298364
PUBLISHER: Allied Market Research | PRODUCT CODE: 1298364
The Cell Analysis Market was valued at $17.1 billion in 2022 and is estimated to reach $42.9 billion by 2032, exhibiting a CAGR of 9.5% from 2023 to 2032. Cell analysis is used to observe and study the structure, composition, and behavior of individual cells. It involves the use of various techniques such as microscopy, flow cytometry, spectrophotometry, and immunoassay to obtain information about the health and activity of cells. It can be used to detect and diagnose diseases, monitor the response to treatments, and investigate the mechanisms of cellular functions.
The major factors that drive the growth of the market are the rise in technological advancement in cell analysis and an increase in the prevalence of chronic diseases such as cancer and genetic disorders. For instance, according to World Health Organization, cancer is a leading cause of death worldwide, which accounted for nearly 10 million deaths in 2020. Breast cancer accounted for the highest number of cases in 2020, with 2.26 million cases, followed by lung cancer with 2.21 million cases. The most common causes of cancer death in 2020 were lung cancer with 1.80 million deaths followed by colon and rectum cancer with 916,000 cases. In addition, the surge in R&D activities in the pharmaceutical & biotechnology industry and rise in focus on personalized medicines further propel the market growth. However, high cost of cell analysis products and the dearth of skilled professionals are anticipated to hamper the market growth in the upcoming years. Conversely, the high growth potential of single-cell sequencing is expected to provide numerous opportunities for market growth during the forecast period.
The cell analysis market is segmented into product, application, technique, end user, and region. By product, the market is bifurcated into consumables, software, services, and instruments. By application, it is segregated into oncology, immunology, cardiology, stem cell, genetic disease, and others. By technique, the market is categorized into flow cytometry, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, and others. On the basis of end-user, it is divided into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include: Becton, Dickinson and Company, Danaher Corporation, QIAGEN N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Agilent Technologies, Inc., Sartorius AG, Biomerieux SA, and Standard BioTools Inc. Key players operating in the market have adopted product launch, product approval, and collaboration as their key strategies to expand their corporate training market share.